benzyloxycarbonylvalyl-alanyl-aspartyl-fluoromethyl-ketone and sphingosine-1-phosphate

benzyloxycarbonylvalyl-alanyl-aspartyl-fluoromethyl-ketone has been researched along with sphingosine-1-phosphate* in 4 studies

Other Studies

4 other study(ies) available for benzyloxycarbonylvalyl-alanyl-aspartyl-fluoromethyl-ketone and sphingosine-1-phosphate

ArticleYear
The Effectiveness of Anti-Apoptotic Agents to Preserve Primordial Follicles and Prevent Tissue Damage during Ovarian Tissue Cryopreservation and Xenotransplantation.
    International journal of molecular sciences, 2021, Mar-03, Volume: 22, Issue:5

    The purpose of this study is to investigate the effectiveness of sphingosine-1-phosphate (S1P) and Z-VAD-FMK (Z-VAD) as anti-apoptotic agents to preserve ovarian function and prevent tissue damage during ovarian tissue cryopreservation and transplantation. This study consisted of two steps, in vitro and in vivo. In the first step, human ovarian tissues were cryopreserved using slow-freezing media alone, S1P, or Z-VAD (control, S1P, Z-VAD group); based on the outcomes in these groups, Z-VAD was selected for subsequent xenotransplantation. In the second step, human frozen/thawed ovarian tissues were grafted into fifty mice divided into three groups: slow-freezing/thawing and transplantation without an anti-apoptotic agent (Trans-control) and xenotransplantation with or without Z-VAD injection (Trans-Z-VAD-positive and Trams-Z-VAD-negative groups, respectively). In the first step, the Z-VAD group had a significantly higher primordial follicular count than the S1P (

    Topics: Adolescent; Adult; Amino Acid Chloromethyl Ketones; Animals; Apoptosis; Cryopreservation; Female; Freezing; Heterografts; Humans; Lysophospholipids; Mice; Mice, SCID; Ovarian Follicle; Sphingosine; Transplantation, Heterologous; Young Adult

2021
Cytoskeletal rearrangement and caspase activation in sphingosine 1-phosphate-induced lung capillary tube formation.
    Stem cells and development, 2004, Volume: 13, Issue:5

    Angiogenesis is a multistep process involving the endothelial cell (EC) cytoskeleton in migration, proliferation, and barrier stabilization. Although precise intracellular pathways by which angiogenic tube formation occurs remain poorly understood, we speculated that interactions between the cytoskeleton and apoptosis are involved and explored cytoskeletal rearrangement and caspase activation in human lung microvascular EC capillary-like tube formation induced by sphingosine 1-phosphate (Sph 1-P) and vascular endothelial growth factor (VEGF). Sph 1-P and VEGF enhance tube formation quantified by a Tube Immaturity Index (TII) generated from the ratio of cell number to tube length, with concomitant morphologic and actomyosin network changes. Angiogenesis was temporally grouped into three stages with early changes characterized by cortical actin localization, whereas midstage tube development demonstrated elongated EC with peripheral actin labeling with transcellular stress fibers. Late tube formation was characterized by broad actin distribution and presence of caspase-positive EC. Phosphorylated MLC immunoreactivity was present at all stages, suggesting that coordinate Rho kinase and MLCK involvement is important to Sph 1-P-induced cell motility; however, chemical inhibition of either MLCK or Rho kinase failed to alter early tube formation. To address whether gaps created by apoptosis expand the lumen, Sph 1-P-induced tubes were differentiated in the presence of caspase inhibitor z-Val-Ala-Asp-fluoromethylketone (zVAD-FMK). Capillary-like tube maturation, but not length, was decreased by zVAD-FMK treatment. These studies suggest that Sph 1-P may induce EC tube formation by regulating early cytoskeletal rearrangement, whereas EC apoptosis within capillary-like tubes is necessary for late stage Sph 1-P-induced tube maturation and lumen formation.

    Topics: Actins; Actomyosin; Amino Acid Chloromethyl Ketones; Apoptosis; Basement Membrane; Capillaries; Caspases; Cell Differentiation; Cell Movement; Cell Proliferation; Collagen; Cytoskeleton; Drug Combinations; Endothelial Cells; Enzyme Activation; Enzyme Inhibitors; Humans; Laminin; Lung; Lysophospholipids; Microcirculation; Microscopy, Fluorescence; Neovascularization, Pathologic; Phosphorylation; Proteoglycans; Sphingosine; Time Factors; Vascular Endothelial Growth Factor A

2004
Activation of caspase-3-like proteases in apoptosis induced by sphingosine and other long-chain bases in Hep3B hepatoma cells.
    The Biochemical journal, 1999, Feb-15, Volume: 338 ( Pt 1)

    Sphingosine and other long-chain bases (including sphinganine, dimethylsphingosine and stearylamine), but not octylamine (a short-chain analogue of sphinganine), induced apoptosis in Hep3B hepatoma cells. Because both D- and L-erythrosphingosine and stearylamine exert potent apoptotic effects on Hep3B cells, it is possible that these long-chain bases may activate apoptosis by inhibiting protein kinase C (PKC) activity. However, pretreatment with the PKC activator PMA could not rescue cells from apoptosis triggered by long-chain bases. Therefore the involvement of PKC in this apoptotic process requires further characterization. We also investigated whether these long-chain bases might be metabolized into ceramide in order to elicit their apoptotic action. We found that long-chain bases acted independently of ceramide in the induction of apoptosis, since addition of fumonisin B1, a fungal agent which effectively inhibits ceramide synthesis from sphingosine, did not protect against apoptosis. Additionally, we found that sphingosine-induced apoptosis was accompanied by activation of caspases. The functional role of caspases in this apoptotic process was examined by using specific caspase inhibitors. The general caspase inhibitor benzyloxycarbonyl-Val-Ala-Asp fluoromethyl ketone, which exhibits a broad specificity for caspase-family proteases, effectively blocked sphingosine-induced apoptosis. Furthermore, our results indicate that caspase-3-like proteases, but not caspase-1, are activated during apoptosis triggered by sphingosine. Enhancement of caspase-3-like activity and cleavage of poly(ADP-ribose) polymerase, an in vivo substrate for caspase-3, was clearly demonstrated in sphingosine-treated Hep3B cells. Considered together, these results suggest that caspase-3-like proteases participate in apoptotic cell death induced by sphingosine.

    Topics: Amino Acid Chloromethyl Ketones; Apoptosis; Carcinoma, Hepatocellular; Caspase 3; Caspase Inhibitors; Caspases; Catalysis; Enzyme Activation; Enzyme Induction; Humans; Lysophospholipids; Poly(ADP-ribose) Polymerases; Sphingosine; Tetradecanoylphorbol Acetate; Tumor Cells, Cultured

1999
Apoptosis-associated signaling pathways are required for chemotherapy-mediated female germ cell destruction.
    Nature medicine, 1997, Volume: 3, Issue:11

    Female sterility resulting from oocyte destruction is an unfortunate, and in many cases inevitable, consequence of chemotherapy. We show that unfertilized mouse oocytes exposed to therapeutic levels of the antitumor drug, doxorubicin (DXR), undergo apoptosis; however, fertilized oocytes do not initiate apoptosis, but enter cell-cycle arrest, when treated with DXR. Apoptosis induced by DXR in oocytes is blocked by sphingosine-1-phosphate, an inhibitor of ceramide-promoted cell death. Oocytes from Bax-deficient, but not p53-null, female mice display complete resistance to DXR-induced apoptosis in vivo and in vitro. Pretreatment of oocytes with a specific peptide inhibitor of caspases also abrogates the apoptotic response to DXR. These findings indicate that oocyte destruction caused by chemotherapy can be prevented by manipulation of apoptosis-associated signaling pathways.

    Topics: Amino Acid Chloromethyl Ketones; Animals; Antibiotics, Antineoplastic; Apoptosis; bcl-2-Associated X Protein; Ceramides; Culture Techniques; Cysteine Proteinase Inhibitors; Doxorubicin; Female; Leukemia P388; Lysophospholipids; Mice; Oocytes; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Signal Transduction; Sphingosine; Tumor Cells, Cultured; Tumor Suppressor Protein p53

1997